SKYE vs SNDL vs LWAY vs MAPS vs CRON

For growth investors, Cronos Group Inc.

(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -5. 3% for WM Technology, Inc. (MAPS). WM Technology, Inc. (MAPS) offers the better valuation at 18. 7x trailing P/E, making it the more compelling value choice. Analysts rate Lifeway Foods, Inc. (LWAY) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, WM Technology, Inc.

(MAPS) is the cheapest at 18. 7x versus Lifeway Foods, Inc. at 28. 8x. On forward P/E, Lifeway Foods, Inc. is actually cheaper at 22. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Lifeway Foods, Inc.

(LWAY) delivered a total return of +461. 4%, compared to -97. 5% for WM Technology, Inc. (MAPS). Over 10 years, the gap is even starker: CRON returned +1439% versus SKYE's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), WM Technology, Inc.

(MAPS) is the lower-risk stock at 0. 52β versus Skye Bioscience, Inc. 's 2. 13β — meaning SKYE is approximately 311% more volatile than MAPS relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 20% for WM Technology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cronos Group Inc.

(CRON) is pulling ahead at 64. 4% versus -5. 3% for WM Technology, Inc. (MAPS). On earnings-per-share growth, the picture is similar: SNDL Inc. grew EPS 84. 1% year-over-year, compared to -100. 0% for Cronos Group Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lifeway Foods, Inc.

(LWAY) is the more profitable company, earning 6. 5% net margin versus -4. 9% for Cronos Group Inc. — meaning it keeps 6. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LWAY leads at 7. 6% versus -1. 5% for CRON. At the gross margin level — before operating expenses — MAPS leads at 94. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Lifeway Foods, Inc.

(LWAY) trades at 22. 9x forward P/E versus 39. 1x for Cronos Group Inc. — 16. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNDL: 175. 3% to $3. 95.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 96), +1439% 10Y return). Skye Bioscience, Inc. (SKYE) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1439%, SKYE: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SKYE (Healthcare) and SNDL (Healthcare) and LWAY (Consumer Defensive) and MAPS (Technology) and CRON (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SKYE is a small-cap quality compounder stock; SNDL is a small-cap quality compounder stock; LWAY is a small-cap quality compounder stock; MAPS is a small-cap quality compounder stock; CRON is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.